Galecto Inc.
03/02/2026 | Press release | Distributed by Public on 03/02/2026 07:06
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.
A live webcast of the Company's presentation will be available under the "News & Events" tab in the Investor Calendar section of the Company's website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto's pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto's pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Media Contact:
Lia Dangelico
Deerfield Group
[email protected]
Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]
Source: Galecto, Inc.
Galecto Inc. published this content on March 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 02, 2026 at 13:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]